Search Results

Contemporary art collage of hand holding an arrow showing fall. Modern design. Copy space.

Cancer

Syros Crashes Over 90% on Late-Stage MDS Fail, Loan Default

With the Phase III failure, Syros will discontinue the study of tamibarotene for myelodysplastic syndrome and will default on its loan from Oxford Finance LLC.

November 13, 2024

·

2 min read

·

Tristan Manalac

Genetown

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 02, 2024

Syros Pharmaceuticals announced the grant of a restricted stock unit award for 8,400 shares of Syros common stock to one newly hired employee in connection with commencing employment with Syros.

April 2, 2024

·

1 min read

Genetown

Syros to Participate in Upcoming May 2024 Investor Conferences

Syros Pharmaceuticals, a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, announced that company management will participate in a fireside chat at two upcoming investor conferences.

May 7, 2024

·

1 min read

Press Releases

Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials

April 15, 2025

·

1 min read

Business

Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended March 31, 2024 and provided a corporate update.

May 14, 2024

·

9 min read

Business

Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024

Syros Pharmaceuticals announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, May 14, 2024 to report its first quarter 2024 financial results and provide a corporate update.

May 7, 2024

·

1 min read

Genetown

Syros to Participate in TD Cowen 44th Annual Health Care Conference

Syros Pharmaceuticals today announced that its Chief Executive Officer, Conley Chee, will participate in a panel discussion at the TD Cowen 44th Annual Health Care Conference.

February 27, 2024

·

1 min read

Genetown

Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene

Syros Pharmaceuticals, a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, highlighted anticipated 2024 milestones to deliver on the value of tamibarotene.

January 8, 2024

·

7 min read

Genetown

Syros to Participate in Upcoming Investor Conferences - November 21, 2023

Syros Pharmaceuticals today announced that company management will participate in a fireside chat at two upcoming investor conferences.

November 21, 2023

·

1 min read

FDA

Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression

Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression.

April 9, 2024

·

6 min read